# CTOR (Citius Oncology, Inc.) - SEC EDGAR Financial Statements

> Citius Oncology, Inc. reported $112.1M in total assets and a net loss of $46.06M through September 30, 2025 from SEC EDGAR filings.

- Canonical: https://convexityos.com/fundamentals/CTOR
- Markdown: https://convexityos.com/fundamentals/CTOR.md
- SEC CIK: 0001851484
- Reporting currency: USD
- Latest filing period: June 30, 2026
- Last synced: Nov 20, 2026, 05:52 UTC
- Primary source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001851484&type=&dateb=&owner=include&count=40)

## Key Financial Metrics

| Metric | Period | Value | Notes |
| --- | --- | --- | --- |
| Revenue | FY 2025 | -- | Sep 30, 2025 |
| Operating Income | FY 2025 | -$47.29M | Operating profit |
| Net Income | FY 2025 | -$46.06M | GAAP bottom line |
| Diluted EPS | FY 2025 | -$0.43 | Split-adjusted |
| Free Cash Flow | FY 2025 | -- | Operating CF less CapEx |
| Cash & ST Investments | Jun 30, 2026 | $16.56M | Total debt: $6.41M |

## Income Statement

### Income Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2023 | FY 2022 |
| --- | --- | --- | --- | --- | --- |
| Research & Development | $6.42M | $4.93M | -- | $4.24M | -- |
| Total Operating Expenses | $23.52M | $20.57M | -- | $12.12M | -- |
| **Operating Income** | -$23.52M | -$20.57M | -$1.01M | -- | -$138K |
| Interest Income | $36K | -- | -- | -- | -- |
| Interest Expense | $218K | -- | -- | -- | -- |
| Income Before Tax | -$23.70M | -$20.57M | -- | -$12.12M | -- |
| Income Tax Expense | $1.06M | $576K | -- | $576K | -- |
| **Net Income** | -$24.76M | -$21.15M | $2.42M | -$12.70M | $381K |
| Basic EPS | -$0.34 | -$0.31 | $0.27 | -$0.19 | $0.12 |
| **Diluted EPS** | -$0.34 | -$0.31 | $0.27 | -$0.19 | $0.12 |
| Basic Shares Outstanding | 73.3M | 68.1M | 6.6M | 67.5M | 1.3M |
| Diluted Shares Outstanding | 73.3M | 68.1M | 6.6M | 67.5M | 1.3M |

### Income Statement (Quarterly)

| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Revenue** | $1.49M | $1.67M | $3.94M | -- | -- | -- | -- | -- |
| Cost of Revenue | $492K | $329K | $789K | -- | -- | -- | -- | -- |
| **Gross Profit** | $1.00M | $1.34M | $3.15M | -- | -- | -- | -- | -- |
| Research & Development | $218K | $1.08M | $1.02M | $1.08M | $938K | $3.14M | $1.26M | $1.30M |
| Total Operating Expenses | $9.72M | $29.95M | $8.41M | $4.71M | $4.94M | $7.47M | $6.39M | $6.67M |
| **Operating Income** | -$8.72M | -$28.61M | -$5.25M | -$4.71M | -$4.94M | -$7.47M | -$6.39M | -- |
| Interest Income | $97K | $44K | $28K | -- | -- | -- | -- | -- |
| Interest Expense | $232K | $33K | $46K | -- | $161K | -- | -- | -- |
| Income Before Tax | -$9.03M | -$26.84M | -$5.27M | -$4.73M | -$5.11M | -$7.47M | -$6.39M | -$6.67M |
| Income Tax Expense | -$107K | -$231K | $264K | $264K | $264K | $264K | $264K | $144K |
| **Net Income** | -$8.92M | -$26.61M | -$5.53M | -$5.00M | -$5.37M | -$7.74M | -$6.66M | -$6.81M |
| Basic EPS | -$0.08 | -$0.27 | -$0.06 | -- | -$0.08 | -$0.11 | -$0.09 | -- |
| **Diluted EPS** | -$0.08 | -$0.27 | -$0.06 | -- | -$0.08 | -$0.11 | -$0.09 | -- |
| Basic Shares Outstanding | 107.9M | 100.0M | 87.5M | -- | 71.6M | 71.6M | 71.6M | -- |
| Diluted Shares Outstanding | 107.9M | 100.0M | 87.5M | -- | 71.6M | 71.6M | 71.6M | -- |

## Balance Sheet

### Balance Sheet (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2023 | FY 2022 | FY 2021 |
| --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $3.92M | $112 | $33K | $27K | $289K | -- |
| **Cash & Short-Term Investments** | $3.92M | $112 | $33K | $27K | $289K | -- |
| Inventory | $22.29M | $8.27M | -- | -- | -- | -- |
| **Total Current Assets** | $27.54M | $10.97M | $58K | $7.73M | $377K | $126K |
| Long-Term Investments | -- | -- | $72.57M | $70.63M | $67.81M | -- |
| **Total Non-Current Assets** | $73.40M | $73.40M | $72.57M | $40.00M | $67.81M | $0 |
| **Total Assets** | $100.9M | $84.37M | $72.62M | $47.73M | $68.19M | $126K |
| Accounts Payable | $13.23M | $3.71M | -- | $1.29M | -- | -- |
| **Total Current Liabilities** | $49.49M | $32.70M | $2.05M | $21.05M | $32K | $137K |
| **Total Non-Current Liabilities** | $6.59M | $5.53M | -- | $1.15M | $0 | $0 |
| **Total Liabilities** | $56.08M | $38.23M | -- | $22.20M | $32K | $137K |
| Common Stock | $8.4K | $7.2K | $167 | $6.8K | $242 | $173 |
| Retained Earnings | -$64.04M | -$39.28M | -$1.99M | -$18.13M | $345K | -$10K |
| **Total Stockholders' Equity** | $44.87M | $46.14M | $22.73M | $25.54M | $346K | -$10K |
| Total Equity | $44.87M | $46.14M | $22.73M | $25.54M | $346K | -$10K |

### Balance Sheet (Quarterly)

| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $16.56M | $2.63M | $7.30M | $3.92M | $112 | $112 | $112 | $112 |
| **Cash & Short-Term Investments** | $16.56M | $2.63M | $7.30M | $3.92M | $112 | $112 | $112 | $112 |
| Accounts Receivable, Net | $686K | $1.08M | $4.05M | -- | -- | -- | -- | -- |
| Inventory | $22.63M | $22.66M | $22.64M | $22.29M | $17.21M | $15.34M | $14.38M | $8.27M |
| **Total Current Assets** | $42.71M | $29.42M | $37.15M | $27.54M | $18.31M | $18.04M | $17.08M | $10.97M |
| **Total Non-Current Assets** | $69.39M | $71.28M | $72.83M | $73.40M | $73.40M | $73.40M | $73.40M | $73.40M |
| **Total Assets** | $112.1M | $100.7M | $110.0M | $100.9M | $91.71M | $91.44M | $90.48M | $84.37M |
| Accounts Payable | $7.32M | $8.88M | $10.45M | $13.23M | $8.67M | $7.68M | $5.87M | $3.71M |
| **Total Current Liabilities** | $58.79M | $58.81M | $44.71M | $49.49M | $52.99M | $49.74M | $43.40M | $32.70M |
| **Total Non-Current Liabilities** | $12.92M | $6.62M | $6.85M | $6.59M | $6.32M | $6.06M | $5.79M | $5.53M |
| **Total Liabilities** | $71.71M | $65.43M | $51.56M | $56.08M | $59.31M | $55.80M | $49.19M | $38.23M |
| **Total Debt (incl. Leases)** | $6.41M | -- | -- | -- | -- | -- | -- | -- |
| Common Stock | $11K | $9.3K | $8.5K | $8.4K | $7.2K | $7.2K | $7.2K | $7.2K |
| Retained Earnings | -$105.1M | -$96.18M | -$69.57M | -$64.04M | -$59.04M | -$53.67M | -$45.94M | -$39.28M |
| **Total Stockholders' Equity** | $40.38M | $35.27M | $58.41M | $44.87M | $32.40M | $35.64M | $41.29M | $46.14M |
| Total Equity | $40.38M | $35.27M | $58.41M | $44.87M | $32.40M | $35.64M | $41.29M | $46.14M |

## Cash Flow Statement

### Cash Flow Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2023 | FY 2022 |
| --- | --- | --- | --- | --- | --- |
| Net Income | -$24.76M | -$21.15M | $2.42M | -$12.70M | $381K |
| Stock-Based Compensation | $8.32M | $7.50M | -- | $1.97M | -- |
| Change in Inventory | -$12.65M | -$2.13M | -- | -- | -- |
| Change in Payables | $9.52M | $2.42M | -- | $1.20M | -- |
| **Operating Cash Flow** | -$5.49M | $126K | -$601K | -- | -$48K |
| **Investing Cash Flow** | -$5.75M | -$5.00M | -$1.32M | -- | -$67.32M |
| Common Stock Issued | $15.17M | -- | -- | -- | $66.00M |
| **Financing Cash Flow** | $15.17M | $4.87M | $1.66M | -- | $67.66M |
| **Net Change in Cash** | $3.92M | $112 | -$256K | -- | $289K |

### Cash Flow Statement (Quarterly)

| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$8.92M | -$26.61M | -$5.53M | -$5.00M | -$5.37M | -$7.74M | -$6.66M | -$6.81M |
| Stock-Based Compensation | $3.56M | $3.53M | $3.96M | $2.30M | $2.13M | $2.09M | $1.81M | $1.67M |
| Change in Receivables | $393K | $2.97M | -$4.05M | -- | -- | -- | -- | -- |
| Change in Inventory | $34K | -$20K | -$353K | -$3.71M | -$1.87M | -$958K | -$6.11M | -- |
| Change in Payables | -$1.57M | -$1.56M | -$2.79M | $4.57M | $991K | $1.80M | $2.16M | $3.71M |
| **Operating Cash Flow** | -$2.71M | -$3.83M | -$7.35M | -- | -- | -- | -- | -- |
| **Investing Cash Flow** | -$2.00M | -$600K | -$4.40M | -- | -- | -- | -- | -- |
| Common Stock Issued | -$818 | -$62K | $15.13M | $15.17M | -- | -- | -- | -- |
| **Financing Cash Flow** | $18.64M | -$231K | $15.13M | -- | -- | -- | -- | -- |
| **Net Change in Cash** | $13.93M | -$4.66M | $3.37M | -- | -- | -- | -- | -- |

## Profitability Ratios & YoY Growth

### Profitability Ratios & YoY Growth (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2023 | FY 2022 |
| --- | --- | --- | --- | --- | --- |
| Return on Equity (ROE) | -55.2% | -45.8% | 10.6% | -49.7% | 110.2% |
| Return on Assets (ROA) | -24.5% | -25.1% | 3.3% | -26.6% | 0.6% |
| Current Ratio | 0.56x | 0.34x | 0.03x | 0.37x | 11.85x |
| Quick Ratio | 0.11x | 0.08x | 0.02x | 0.00x | 9.08x |
| **Net Income Growth (YoY)** | -- | -- | +535.3% | -- | -- |
| EPS Growth (YoY) | -- | -- | +125.0% | -- | -- |
| Operating Cash Flow Growth (YoY) | -4446.6% | -- | -- | -- | -- |

### Profitability Ratios & YoY Growth (Quarterly)

| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Return on Equity (ROE) | -114.1% | -120.5% | -40.5% | -55.2% | -82.0% | -72.9% | -55.9% | -45.8% |
| Return on Assets (ROA) | -41.1% | -42.2% | -21.5% | -24.5% | -29.0% | -28.4% | -25.5% | -25.1% |
| Current Ratio | 0.73x | 0.50x | 0.83x | 0.56x | 0.35x | 0.36x | 0.39x | 0.34x |
| Quick Ratio | 0.34x | 0.12x | 0.32x | 0.11x | 0.02x | 0.05x | 0.06x | 0.08x |
| Debt to Equity | 0.16x | -- | -- | -- | -- | -- | -- | -- |
| **Net Income Growth (YoY)** | -- | -- | -- | -- | -- | -- | -- | -4413.5% |

## Related Companies

[AMZN (Amazon.com, Inc.)](https://convexityos.com/fundamentals/AMZN), [WMT (Walmart Inc.)](https://convexityos.com/fundamentals/WMT), [AAPL (Apple Inc.)](https://convexityos.com/fundamentals/AAPL), [GOOG (Alphabet Inc.)](https://convexityos.com/fundamentals/GOOG), [UNH (UnitedHealth Group Incorporated)](https://convexityos.com/fundamentals/UNH), [CVS (CVS HEALTH Corp)](https://convexityos.com/fundamentals/CVS), [MCK (McKESSON CORPORATION)](https://convexityos.com/fundamentals/MCK), [BRK-A (Berkshire Hathaway Inc.)](https://convexityos.com/fundamentals/BRK-A)

---

## About Convexity

Published by [Convexity](https://convexityos.com/), a primary-source financial intelligence terminal built on SEC EDGAR filings, XBRL financial statements, options, macro data, and cited AI research. Free tier with no card and published prices at https://convexityos.com/pricing; Streamable HTTP MCP server at https://convexityos.com/mcp; full site index at https://convexityos.com/llms.txt.
